Skip to main content
Premium Trial:

Request an Annual Quote

Catching the Eye of Pharma

Derek Lowe is intrigued by NIH's latest announcement that it is beginning a preclinical drug discovery endeavor for rare diseases and says that it'll be a good learning experience for researchers to see the difficulties involved in getting a drug through the development process. He adds that the NIH, judging by its release, is clear-eyed about the process. "If they can get some things to the point that a company or foundation is willing to take on the (now somewhat reduced) risks, that'll be great," Lowe says. The Wall Street Journal's Health Blog adds that NIH will be spending about $24 million per year to get these potential drugs through the preclinical stage.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.